178 Total Tumor Volume (TTV) Predicts Recurrence of Hepatocellular Carcinoma (HCC) Post Liver Transplantation (LT) in Patients Beyond Milan or UCSF Criteria and May Optimize Selection of LT Candidates

2009 ◽  
Vol 136 (5) ◽  
pp. A-795
Author(s):  
Carole Macaron ◽  
Ibrahim Hanouneh ◽  
Rocio Lopez ◽  
Federico N. Aucejo ◽  
Nizar N. Zein
Hepatology ◽  
2015 ◽  
Vol 62 (1) ◽  
pp. 158-165 ◽  
Author(s):  
Christian Toso ◽  
Glenda Meeberg ◽  
Roberto Hernandez-Alejandro ◽  
Jean-François Dufour ◽  
Paul Marotta ◽  
...  

2018 ◽  
Vol 35 (6) ◽  
pp. 539-548
Author(s):  
Hugo Pinto-Marques ◽  
Silvia Silva ◽  
Mafalda Sobral ◽  
Rui Perdigoto ◽  
Américo Martins ◽  
...  

Total tumor volume (TTV) has been proposed as a more accurate means of selecting patients for liver transplantation (LT) due to hepatocellular carcinoma (HCC). We aim to analyze the role of TTV in a population with a short waiting time on list. Methods: Analysis of a prospective database of patients submitted to LT for HCC between September 1992 and February 2014. TTV, Milan criteria (MC), UCSF (University of California San Francisco), and “Up to Seven” criteria were calculated both with preoperative imaging exams and histological data. Results: The study population consisted of 231 out of patients. Median waiting time on list was 62.5 days. MC included 187 patients, while TTV ≤115 cm3 included 214. Microvascular invasion (HR 2.601, 95% CI 1.529–4.426), MC (HR 1.666, 95% CI 0.990–2.804), UCSF criteria (HR 2.995, 95% CI 1.875–4.875), TTV ≤115 cm3 (HR 2.898, 95% CI 1.398–6.007), and “Up to Seven” criteria (HR 2.139, 95% CI 1.353–3.383) proved to be independent factors for prognosis for disease-free survival. Conclusions: TTV ≤115 cm3 may be a useful tool to properly identify the best HCC candidates for LT in a population with a short waiting time on list. TTV gives more patients the opportunity of undergoing LT while maintaining similar rates of tumor recurrence and patient survival.


2008 ◽  
Vol 14 (8) ◽  
pp. 1107-1115 ◽  
Author(s):  
Christian Toso ◽  
James Trotter ◽  
Alice Wei ◽  
David L. Bigam ◽  
Shimul Shah ◽  
...  

2019 ◽  
Author(s):  
Tsung-Han Wu ◽  
Chih-Hsien Cheng ◽  
Chen-Fang Lee ◽  
Ting-Jung Wu ◽  
Hong-Shiue Chou ◽  
...  

Abstract Background The study analyzed the loco-regional therapy outcomes prior to living donor liver transplantation (LDLT), to provide additional information for decision-making regarding therapeutic strategy for hepatocellular carcinoma (HCC) patients. Methods A total of 308 consecutive patients undergoing LDLTs for HCC between August 2004 and December 2018 were retrospectively analyzed. Patients subjected to loco-regional therapy prior to LT were grouped and the outcomes were compared. Results Overall, HCC recurrence after LDLT were detected in 38 patients (12.3%) during the follow-up period. By the end of the study, 205 patients, 6 of whom with recurrent HCC, were alive. Patients who had radiological imaging beyond the University of California at San Francisco (UCSF) criteria had significant inferior outcomes for both recurrence-free survival (RFS, p = 0.0005) and overall survival (OS, p = 0.0462) despite receiving loco-regional therapy as down-staging intention. Moreover, patients with profound tumor necrosis (TN) had a superior RFS at 3 and 5 years (97.4% and 93.8%, respectively), compared with others. Conclusion LDLT gains a satisfactory result based on the expanded UCSF criteria for HCC. However, the loco-regional therapy prior to LDLT does not seem to provide benefit unless a profound TN is noted.


Sign in / Sign up

Export Citation Format

Share Document